Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2016-08-27T04:08:46Z | - |
dc.date.available | 2016-08-27T04:08:46Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 0001-5792 | * |
dc.identifier.issn | 1421-9662 | * |
dc.identifier.other | OAK-15248 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/217378 | - |
dc.description.abstract | Azacitidine (AZA) is commonly used in patients with myelo-dysplastic syndrome (MDS). To determine the role of AZA before allogeneic stem cell transplantation (allo-SCT), we conducted a prospective study of AZA pre-treatment followed by allo-SCT in patients with higher-risk MDS. Twentyone patients who were scheduled for their third to sixth cycle of AZA pre-treatment followed by allo-SCT were enrolled. AZA pre-treatment was interrupted early in 3 patients (14.3%) because of leukaemic transformation or death. The overall response rate to AZA pre-treatment was 57.1%. There were 2 cases of complete remission, 1 case of partial remission, and 9 cases of haematologic improvement. Fourteen patients (66.7%) received the planned allo-SCT and 5 patients were alive at the last follow-up. Three-year progression-free survival (PFS) and 3-year overall survival (OS) in the 14 patients who received allo-SCT were 30.0% (95% CI 3.3-56.7) and 42.9% (95% CI 17.1-68.7), respectively. PFS and OS were not influenced by response to AZA pre-treatment (p > 0.05). In this study, AZA had a role as a bridge therapy to prevent leukaemic transformation prior to selection of a donor for allo-SCT and showed low toxicity. It may be considered in patients with higher-risk MDS. (C) 2015 S. Karger AG, Basel | * |
dc.language | English | * |
dc.publisher | KARGER | * |
dc.subject | Myelodysplastic syndrome | * |
dc.subject | Azacitidine | * |
dc.subject | Allogeneic stem cell transplantation | * |
dc.title | Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 134 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 40 | * |
dc.relation.lastpage | 48 | * |
dc.relation.journaltitle | ACTA HAEMATOLOGICA | * |
dc.identifier.doi | 10.1159/000368711 | * |
dc.identifier.wosid | WOS:000356978200007 | * |
dc.author.google | Ahn, Jae-Sook | * |
dc.author.google | Kim, Yeo-Kyeoung | * |
dc.author.google | Min, Yoo Hong | * |
dc.author.google | Cheong, June-Won | * |
dc.author.google | Jang, Jun Ho | * |
dc.author.google | Jung, Chul Won | * |
dc.author.google | Kim, In Ho | * |
dc.author.google | Yoon, Hwi-Joong | * |
dc.author.google | Lee, Hong Ghi | * |
dc.author.google | Sohn, Sang Kyun | * |
dc.author.google | Moon, Joon Ho | * |
dc.author.google | Kim, Hawk | * |
dc.author.google | Kim, Yoo-Jin | * |
dc.author.google | Won, Jong-Ho | * |
dc.author.google | Chung, Joo-Seop | * |
dc.author.google | Mun, Yeung Chul | * |
dc.author.google | Lee, Je-Hwan | * |
dc.author.google | Kim, Hyeoung-Joon|Korean Soc Hematology AML MDS Work | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |